

<b>Reference number</b>
1709-H

## SPECIALTY QUANTITY LIMIT PROGRAM

### SANDOSTATIN (octreotide acetate) SANDOSTATIN LAR Depot (octreotide acetate for injectable suspension)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

#### II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Sandostatin (octreotide) Inj 50 mcg/mL	90 per 30 days	<p>Acromegaly:</p> <ul style="list-style-type: none"> <li>Recommended starting dose is 50 mcg three times daily. Adjust thereafter based on GH, IGF-1 levels and/or clinical symptoms.</li> <li>The dose most commonly found to be effective is 100 mcg three times daily, but some patients require up to 500 mcg three times daily, for maximum effectiveness.</li> </ul> <p>Carcinoid tumors:</p> <ul style="list-style-type: none"> <li>Recommended dose during the first 2 weeks ranges from 100-600 mcg/day in 2-4 divided doses</li> <li>Daily maintenance dose ranges from 50 mcg/day to 1500 mcg/day.</li> </ul> <p>Vasoactive intestinal peptide tumors (VIPomas):</p> <ul style="list-style-type: none"> <li>Recommended dose during the first 2 weeks ranges from 200-300 mcg in 2-4 divided doses</li> <li>Dosage may be adjusted to achieve a therapeutic response</li> <li>Usually doses above 450 mcg/day are not required</li> </ul>
Sandostatin (octreotide) Inj 100 mcg/mL	90 per 30 days	
Sandostatin (octreotide) Inj 500 mcg/mL	90 per 30 days	
Sandostatin (octreotide) Inj 200 mcg/mL (5 mL multi-dose vials)	45 vials (45,000 units) per 30 days	
Sandostatin (octreotide) Inj 1000 mcg/mL (5 mL multi-dose vials)	9 vials (45,000 units) per 30 days	
Sandostatin (octreotide) Kit LAR 10 mg	10 mg (1 Kit) per 28 days	<p>Acromegaly:</p> <ul style="list-style-type: none"> <li>Recommended starting dose is 20 mg every 4 weeks for 3 months. Adjust thereafter based on GH, IGF-1 levels and/or clinical symptoms.</li> <li>Doses higher than 40 mg are not recommended</li> </ul>
Sandostatin (octreotide) Kit LAR 20 mg	40 mg (2 Kits) per 28 days	

<b>Reference number</b>
1709-H

<b>Medication</b>	<b>Standard Limit</b>	<b>FDA-recommended dosing</b>
Sandostatin (octreotide) Kit LAR 30 mg	30 mg (1 Kit) per 28 days	<p>Carcinoid tumors and vasoactive intestinal peptide tumors (VIPomas):</p> <ul style="list-style-type: none"> <li>20 mg every 4 weeks for 2 months. Adjust dosage thereafter based on symptoms. Doses higher than 30 mg are not recommended.</li> </ul> <p>Renal impairment – patients on dialysis:</p> <ul style="list-style-type: none"> <li>10 mg every 4 weeks</li> </ul> <p>Hepatic impairment – patients with cirrhosis:</p> <ul style="list-style-type: none"> <li>10 mg every 4 weeks</li> </ul>

\*The standard limits may apply to the generic equivalent medications.

### III. REFERENCES

1. Sandostatin [package insert]. Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.
2. Sandostatin LAR Depot [package insert]. Hanover, NJ: Novartis Pharmaceuticals Corporation; December 2018.